Abstract
Ceftazidime-avibactam is a combination of a third-generation cephalosporin and a novel non-beta-lactam beta-lactamase inhibitor. This combination was recently recommended for the treatment of complicated urinary tract infections, including acute pyelonephritis, in adults with limited or no alternative treatment options. The current review is aimed to determine activity, efficacy and safety of ceftazidime-avibactam in the treatment of patients with complicated urinary tract infections.
Keywords:
antibiotics; antimicrobial agents; avibactam; beta lactamase; beta-lactams; ceftazidime; ceftazidime drug combination; pyelonephritis; urinary tract infections.
MeSH terms
-
Adult
-
Azabicyclo Compounds / adverse effects
-
Azabicyclo Compounds / chemistry
-
Azabicyclo Compounds / metabolism
-
Azabicyclo Compounds / pharmacology
-
Azabicyclo Compounds / therapeutic use*
-
Ceftazidime / adverse effects
-
Ceftazidime / chemistry
-
Ceftazidime / metabolism
-
Ceftazidime / pharmacology
-
Ceftazidime / therapeutic use*
-
Drug Combinations
-
Drug Resistance, Multiple, Bacterial
-
Escherichia coli / drug effects
-
Female
-
Humans
-
Intraabdominal Infections / drug therapy
-
Intraabdominal Infections / microbiology
-
Male
-
Molecular Weight
-
Pyelonephritis / drug therapy
-
Urinary Tract Infections / complications*
-
Urinary Tract Infections / drug therapy*
-
Urinary Tract Infections / microbiology
-
beta-Lactamase Inhibitors / adverse effects
-
beta-Lactamase Inhibitors / pharmacology
-
beta-Lactamase Inhibitors / therapeutic use*
Substances
-
Azabicyclo Compounds
-
Drug Combinations
-
avibactam, ceftazidime drug combination
-
beta-Lactamase Inhibitors
-
avibactam
-
Ceftazidime